Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Supportive Care and Monitoring in Intracerebral Hemorrhage

Supportive Care and Monitoring in Intracerebral Hemorrhage

Objective

  • Recommend appropriate supportive care and monitoring strategies to prevent complications and optimize outcomes in intracerebral hemorrhage.

1. Continuous Neurological Monitoring

Frequent assessment of consciousness and brainstem function is essential to detect early deterioration.

Glasgow Coma Scale (GCS)

  • Frequency: Hourly to bi-hourly during the first 72 hours; can extend to every 4 hours once stable.
  • Components:
    • Eye Opening (E): 1–4 points
    • Verbal Response (V): 1–5 points
    • Motor Response (M): 1–6 points
    • Total Score: 3–15
  • Trending: Document each component and graph changes to catch subtle declines.

Pupillary Checks

  • Assess size (in mm), symmetry, and light reactivity at the same intervals as GCS.
  • Anisocoria (>1 mm difference) or sluggish reaction may herald herniation.
Key Pearls: Neurological Monitoring
  • A 1–2-point drop in GCS often precedes radiographic hematoma expansion.
  • Pupillary asymmetry can occur before vital sign changes in transtentorial herniation.

2. Intracranial Pressure Monitoring

In patients at high risk for elevated ICP, monitoring guides therapy and prognostication.

Indications

  • GCS ≤ 8 with CT evidence of large hematoma or intraventricular extension.
  • Clinical signs of raised ICP: headache, vomiting, bradycardia with hypertension (Cushing’s triad).

Modalities

  • External ventricular drain (EVD): Measures ICP and allows CSF drainage; risk of infection.
  • Intraparenchymal probe: Continuous pressure recording; no drainage capability.

Interpretation & Thresholds

ICP Monitoring Parameters and Therapeutic Targets
Parameter Value/Target Interventions & Notes
Normal ICP < 20 mmHg Maintain if possible.
Treatment Threshold for ICP Sustained > 20–25 mmHg Elevate head of bed to 30°, therapeutic CSF drainage (if EVD in situ), hyperosmolar therapy (hypertonic saline or mannitol).
Target Cerebral Perfusion Pressure (CPP) 60–70 mmHg Calculated as Mean Arterial Pressure (MAP) – ICP. Requires arterial line and ICP monitor.
Key Pearls: ICP Management
  • Choose EVD in ICH with hydrocephalus; intraparenchymal probe may be considered in deep parenchymal bleeds without significant hydrocephalus or mass effect requiring CSF diversion.
  • Drain CSF slowly (e.g., 5-10 mL aliquots or continuous drainage at a set pressure level) to avoid rapid CPP swings and potential herniation.
Editor’s Note: Procedural Details

Insufficient source material for device insertion techniques, zeroing protocols, and infection-prevention bundles. A complete section on ICP monitoring would typically include details on:

  • Aseptic insertion protocols for EVDs and intraparenchymal probes.
  • Waveform interpretation (e.g., P1, P2, P3 waves).
  • Calibration and zeroing procedures for transducers.
  • Strategies for weaning from ICP monitoring and EVD drainage.
  • Bundled interventions to prevent EVD-related infections.

3. Prevention of Secondary Brain Injury

Maintain optimal physiologic parameters to protect perihematomal tissue.

  • Oxygenation: Target PaO₂ > 80 mmHg via supplemental O₂ or mechanical ventilation. Avoid hypoxia.
  • Ventilation: Maintain PaCO₂ 35–45 mmHg. Reserve brief hyperventilation (PaCO₂ ~ 30 mmHg for ≤ 1–2 hrs) for acute ICP crises only, as a bridge to more definitive therapy.
  • Glycemic Control: Aim for blood glucose levels of 140–180 mg/dL (7.8–10.0 mmol/L) with insulin infusion if necessary. Avoid hypoglycemia (< 70 mg/dL or < 3.9 mmol/L).
  • Temperature Management: Maintain normothermia (36.0–37.5 °C) with antipyretics and surface or endovascular cooling devices if fever occurs. Prophylactic hypothermia is not recommended.
Key Pearls: Secondary Injury Prevention
  • Prolonged hyperventilation risks cerebral ischemia due to vasoconstriction; use only as a temporizing measure in emergency ICP elevations.
  • Continuous glucose monitoring, if available, can reduce the incidence and duration of unrecognized hypoglycemic episodes.
  • Treat fever aggressively as it can worsen secondary brain injury.

4. Complication Surveillance and Management

Early prevention and treatment of systemic and neurologic complications are critical.

  • Seizures
    • Prophylaxis: Not routinely recommended in seizure-free patients. Continuous EEG monitoring may be considered in patients with fluctuating mental status.
    • Treatment: Levetiracetam 500–1500 mg IV/PO q12h is a common first-line agent; adjust dose for renal function. Treat clinical seizures promptly.
  • Venous Thromboembolism (VTE)
    • Initiate intermittent pneumatic compression (IPC) devices on day 1 for all immobile patients.
    • Consider low-dose unfractionated heparin or low-molecular-weight heparin (LMWH) for VTE prophylaxis at 24–48 hours after ICH onset if a repeat CT scan confirms hematoma stability.
  • Infection Prevention
    • Implement VAP (Ventilator-Associated Pneumonia) and CAUTI (Catheter-Associated Urinary Tract Infection) bundles: head-of-bed elevation (30-45 degrees for VAP), oral care with chlorhexidine, daily review of necessity for invasive lines and catheters.
    • Minimize duration of invasive lines and catheters.
  • Electrolyte Management
    • Sodium: Target normonatremia (typically 135–145 mEq/L). Correct hyponatremia based on etiology (e.g., SIADH vs. cerebral salt wasting). Avoid rapid correction.
    • Maintain potassium > 4.0 mEq/L and magnesium > 2.0 mg/dL to reduce arrhythmia and potential seizure risk.
Key Pearls: Complication Management
  • Early initiation of IPC devices significantly lowers VTE risk without increasing the risk of rebleeding.
  • Distinguishing SIADH (syndrome of inappropriate antidiuretic hormone secretion) from cerebral salt wasting is crucial for appropriate fluid and sodium management to correct hyponatremia safely. SIADH often involves eu-/hypervolemia, while CSW involves hypovolemia.

5. Sedation Interruptions and Daily Neurological Evaluations

Balancing adequate sedation with the need for accurate neurologic exams and delirium prevention.

Sedation Vacations (Daily Interruption of Sedation)

  • Safety criteria: Stable hemodynamics, controlled ICP (if monitored), no active seizures, no escalating sedative requirements for agitation.
  • Monitoring during interruption: Assess for agitation, pain, ventilator asynchrony, and ICP spikes. Resume sedation at a lower dose if tolerated, or previous dose if needed.

Delirium Screening and Management

  • Use a validated screening tool like the Confusion Assessment Method for the ICU (CAM-ICU) at least once daily in at-risk patients.
  • Employ nonpharmacologic strategies first: optimize sleep hygiene, frequent reorientation, early mobilization, address sensory impairments (hearing aids, glasses). Minimize use of benzodiazepines.
Key Pearls: Sedation and Delirium
  • Daily sedation breaks can improve the accuracy of neurological assessments, facilitate ventilator weaning, and may shorten ICU length of stay.
  • Prefer easily titratable, short-acting sedatives like propofol or dexmedetomidine over benzodiazepines to reduce delirium incidence and duration in critically ill patients.

6. Early Rehabilitation and Multidisciplinary Coordination

Early, coordinated rehabilitation drives better functional outcomes.

Mobilization Criteria

  • Hemodynamically stable without escalating vasopressor support.
  • Controlled ICP (if monitored) and no new or worsening neurologic deficits.
  • Secure airway (if intubated) and stable respiratory status.

Therapy Integration

  • Physical Therapy (PT): Early activities include bed mobility, passive/active range-of-motion exercises, progressing to sitting, standing, and ambulation as tolerated.
  • Occupational Therapy (OT): Focus on activities of daily living (ADLs), cognitive assessments, and recommendations for adaptive equipment.
  • Speech Therapy (ST): Perform swallowing assessment (dysphagia screening) before oral intake, and provide communication support for aphasia or dysarthria.
Key Pearls: Rehabilitation
  • Initiate rehabilitation therapies, including out-of-bed mobilization, within 24–72 hours in medically stable patients to maximize recovery potential and reduce complications of immobility.
  • Care within a dedicated multidisciplinary stroke unit, which inherently involves coordinated rehabilitation, has been shown to reduce mortality and improve long-term independence.

7. ICU De-escalation and Transition Planning

Structured criteria and communication tools ensure safe transfer to lower acuity settings.

Step-down Criteria (from ICU to a lower level of care)

  • Stable GCS for ≥ 24 hours.
  • No active ICP monitoring or need for acute ICP management.
  • Ventilator weaning initiated or successfully extubated; stable respiratory status on minimal support.
  • No anticipated acute neurosurgical interventions.
  • Absence of other unstable medical conditions requiring ICU-level care.

Handoff Process

  • Utilize a standardized communication tool such as SBAR (Situation, Background, Assessment, Recommendation).
  • Clearly document current neurological status, goals of care, pending studies, medication reconciliation, and specific follow-up plans.
Key Pearls: Transition of Care
  • Standardized handoff protocols reduce communication errors and improve the safety and continuity of care during transitions.
  • Early and proactive transition planning, involving the multidisciplinary team, can help avoid unnecessarily prolonged ICU stays once a patient meets criteria for a lower level of care.

8. Patient and Family Education and Support

Engaging patients (where possible) and caregivers in prognosis discussions and care planning enhances shared decision-making and aligns care with patient values.

Prognosis Communication

  • Use validated prognostic tools (e.g., ICH Score) in conjunction with clinical context; provide information in an understandable manner, balancing realism with hope.
  • Allow ample time for questions and emotional processing; revisit prognosis discussions as the patient’s clinical status evolves.

Goals of Care & Advance Directives

  • Explore patient values and previously expressed wishes regarding life-sustaining treatments. Document preferences early, but avoid making premature decisions on Do-Not-Attempt-Resuscitation (DNAR) orders within the first 24-48 hours unless clearly aligned with pre-existing patient wishes or futility.
  • Reassess goals of care decisions regularly, especially after the initial 48–72 hours when the clinical trajectory often becomes clearer.

Support Resources

  • Involve social work, palliative care specialists, and rehabilitation coordinators early to provide psychosocial support and assist with discharge planning.
  • Provide information on community support groups, financial assistance programs, and home care services as appropriate.
Key Pearls: Patient and Family Engagement
  • Very early (e.g., within the first 24 hours) implementation of DNAR orders has been linked to increased mortality, potentially due to self-fulfilling prophecy; it’s often prudent to allow a period of maximal medical therapy before finalizing such decisions, unless clearly concordant with long-standing patient wishes or in cases of devastating, unsurvivable injury.
  • Structured, empathetic, and values-based communication with families can improve satisfaction with care, reduce decisional conflict, and ensure better alignment of treatment with patient preferences.

References

  1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. Stroke. 2022;53:e282–e361.
  2. Cook AM, Jones GM, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020;32:647–666.
  3. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Acute Intracerebral Hemorrhage: ATACH-2 Trial. N Engl J Med. 2016;375:1033–1043.
  4. Anderson CS, Heeley E, Huang Y, et al. Rapid Blood-Pressure Lowering in Acute ICH: INTERACT2 Trial. N Engl J Med. 2013;368:2355–2365.
  5. Langhorne P, Fearon P; Stroke Unit Trialists’ Collaboration. Stroke unit care benefits patients with ICH: systematic review. Stroke. 2013;44:3044–3049.
  6. Candelise L, Gattinoni M, Bersano A, et al. Stroke unit care for acute stroke patients: meta-analysis of RCTs. Stroke. 2007;38:2926–2932.
  7. Zahuranec DB, Brown DL, Lisabeth LD, et al. Early care limitations independently predict mortality after ICH. Neurology. 2007;68:1651–1657.
  8. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous ICH: AHA/ASA Update. Stroke. 2015;46:2032–2060.
  9. Hanley DF, Lane K, McBee N, et al. CLEAR III Trial: Intraventricular Thrombolysis in Severe Stroke. Lancet. 2017;389:603–611.